Portal for patients

A New Drug For The Treatment Of Obesity Entered The U.S. Market

Food and Drug Administration (FDA) has allowed the use of hypoglycemic agent liraglutide as anti-obesity drug. Developed by Novo Nordisk, it will be marketed under the trade name Saksenda.

A New Drug For The Treatment Of Obesity Entered The U.S. Market

Liraglutide can be used for the treatment of obese adults with at least one weight-related disease (type 2 diabetes, high blood pressure or high cholesterol).

The drug was approved by the FDA for the treatment of type 2 diabetes in 2010.As an antidiabeticmedication liraglutide is sold under the trade name Viktoza. It is worth noting that Saksenda contains a higher dose of liraglutide than Viktoza does.

Studies have shown that liraglutide (3 mg daily) helps patients lose at least 5% of their weight in 50% cases, while 22% of the patients achieve 10% percent weight loss .

See also:


No comments

Application for treatment
Sex
MTEC 2019 (eng.-com)